241 related articles for article (PubMed ID: 35858585)
1. Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer.
Jiang L; You C; Xiao Y; Wang H; Su GH; Xia BQ; Zheng RC; Zhang DD; Jiang YZ; Gu YJ; Shao ZM
Cell Rep Med; 2022 Jul; 3(7):100694. PubMed ID: 35858585
[TBL] [Abstract][Full Text] [Related]
2. Radiomic analysis on magnetic resonance diffusion weighted image in distinguishing triple-negative breast cancer from other subtypes: a feasibility study.
Wang Q; Mao N; Liu M; Shi Y; Ma H; Dong J; Zhang X; Duan S; Wang B; Xie H
Clin Imaging; 2021 Apr; 72():136-141. PubMed ID: 33242692
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
4. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer.
Su GH; Xiao Y; Jiang L; Zheng RC; Wang H; Chen Y; Gu YJ; You C; Shao ZM
J Transl Med; 2022 Oct; 20(1):471. PubMed ID: 36243806
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography.
Feng Q; Hu Q; Liu Y; Yang T; Yin Z
BMC Cancer; 2020 Jun; 20(1):579. PubMed ID: 32571245
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
[TBL] [Abstract][Full Text] [Related]
7. Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets.
Zhang Y; You C; Pei Y; Yang F; Li D; Jiang YZ; Shao Z
J Transl Med; 2022 Jun; 20(1):256. PubMed ID: 35672824
[TBL] [Abstract][Full Text] [Related]
8. MRI Radiomic Features: Association with Disease-Free Survival in Patients with Triple-Negative Breast Cancer.
Kim S; Kim MJ; Kim EK; Yoon JH; Park VY
Sci Rep; 2020 Feb; 10(1):3750. PubMed ID: 32111957
[TBL] [Abstract][Full Text] [Related]
9. Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer.
Lin L; Li H; Wang X; Wang Z; Su G; Zhou J; Sun S; Ma X; Chen Y; You C; Gu Y
Cancer Med; 2023 Dec; 12(24):21639-21650. PubMed ID: 38059408
[TBL] [Abstract][Full Text] [Related]
10. Development of an immune-related prognostic biomarker for triple-negative breast cancer.
Zhang Y; Wang Q; Yang WK; Wang YS; Zhou Q; Lin J; Wei XX; Liang T; Liu T; Fan WT; Liang L; Xu YN
Ann Med; 2022 Dec; 54(1):1212-1220. PubMed ID: 35481432
[No Abstract] [Full Text] [Related]
11. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of radiomics technology based on X-ray mammography in patients with triple-negative breast cancer.
Zhang HX; Sun ZQ; Cheng YG; Mao GQ
J Xray Sci Technol; 2019; 27(3):485-492. PubMed ID: 31081797
[TBL] [Abstract][Full Text] [Related]
13. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
[TBL] [Abstract][Full Text] [Related]
14. Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results.
Leithner D; Horvat JV; Marino MA; Bernard-Davila B; Jochelson MS; Ochoa-Albiztegui RE; Martinez DF; Morris EA; Thakur S; Pinker K
Breast Cancer Res; 2019 Sep; 21(1):106. PubMed ID: 31514736
[TBL] [Abstract][Full Text] [Related]
15. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging.
Kim JJ; Kim JY; Suh HB; Hwangbo L; Lee NK; Kim S; Lee JW; Choo KS; Nam KJ; Kang T; Park H
Eur Radiol; 2022 Feb; 32(2):822-833. PubMed ID: 34345946
[TBL] [Abstract][Full Text] [Related]
16. Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
Kamiya S; Satake H; Hayashi Y; Ishigaki S; Ito R; Kawamura M; Taoka T; Iwano S; Naganawa S
Breast Cancer; 2022 Jan; 29(1):164-173. PubMed ID: 34529241
[TBL] [Abstract][Full Text] [Related]
17. Association between MRI Features and Standardized Uptake Value of 18F-FDG PET/CT in Triple-Negative Breast Cancer.
Choi BB; Lee JS; Kim KH
Oncol Res Treat; 2018; 41(11):706-711. PubMed ID: 30321870
[TBL] [Abstract][Full Text] [Related]
18. Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy.
Ma M; Gan L; Liu Y; Jiang Y; Xin L; Liu Y; Qin N; Cheng Y; Liu Q; Xu L; Zhang Y; Wang X; Zhang X; Ye J; Wang X
Eur J Radiol; 2022 Jan; 146():110095. PubMed ID: 34890936
[TBL] [Abstract][Full Text] [Related]
19. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
20. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
